Increased interest in oncolytic viruses from pharma is noted, with advantages like IV injection over intratumoral delivery. Collaboration with GCAR for pancreatic cancer trial launch is in progress. Pelareorep targets post-ADC therapy patients, offering a potential market opportunity.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay